Nasal vaccines for respiratory infections

• 成果类型: Review
• 署名作者: Kiyono, Hiroshi; Ernst, Peter B.
• 署名单位: University of California System; University of California San Diego; University of California System; University of California San Diego; Chiba University; Chiba University; University of California System; University of California Davis
• 刊物名称: Nature
• ISSN/ISSBN: 0028-2348
• DOI: 10.1038/s41586-025-08910-6
• 发表日期: 2025-05-08
• 页码: 321-330
• 关键词: protein-a pspa; influenza-virus infection; mucosal immune-system; syncytial virus; intranasal immunization; sars-cov-2 vaccine; delivery system; young-children; upper airway; adults

摘要

Beginning with Edward Jenner's discovery of the smallpox vaccine, the ever-expanding repertoire of vaccines against pathogens has saved many lives. During the COVID-19 pandemic, a revolutionary mRNA injectable vaccine emerged that effectively controlled the severity of disease caused by SARS-CoV-2. This vaccine induced potent antigen-specific neutralizing serum IgG antibodies, but was limited in its ability to prevent viral invasion at the respiratory surfaces. Nasal vaccines have attracted attention as a potential strategy to combat respiratory infections and prepare for future pandemics. Input from disciplines such as microbiology, biomaterials, bioengineering and chemistry have complemented the immunology to create innovative delivery systems. This approach to vaccine delivery has yielded nasal vaccines that induce secretory IgA as well as serum IgG antibodies, which are expected to prevent pathogen invasion, thereby diminishing transmission and disease severity. For a nasal vaccine to be successful, the complexity of the relevant anatomical, physiological and immunological properties, including the proximity of the central nervous system to the nasal cavity, must be considered. In this Review, we discuss past and current efforts as well as future directions for developing safe and effective nasal vaccines for the prevention of respiratory infections.